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inclusion criteria. Adherence was measured through prospective
cohort studies (N = 3), retrospective analysis of registries (N = 2)
or claims databases (N = 2). Five of the seven studies were based
in Europe and the remainder in the U.S. Adherence measures
reported included medication possession ratios ([MPR], N = 2)
and discontinuation rates based on physician interviews (N = 4)
or patient self-reports (N = 1).Of studies reportingMPRs, 50% to
80% of patients had a MPR  0.80 during the course of therapy.
Studies measuring discontinuation found the percentage of
patients continuing therapy to range from 45% to 79% after one
year of monotherapy. Adherence rates decreased in subsequent
years of treatment. Combination with methotrexate or other
oral RA drugs was associated with higher (N = 2) and lower
(N = 2) adherence rates.CONCLUSIONS: Few studies have mea-
sured adherence to biologics among RA patients; however, most
ﬁnd adherence to such agents is suboptimal. Methods of adher-
ence measurement varied greatly across studies. Standardized
methods to measure and track adherence to biologics are needed
as their use continues to increase.
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OBJECTIVES: Bevacizumab is approved in metastatic non-
small cell lung cancer and is currently tested in adjuvant lung
cancer trials. In this context we explore the potential costs and
health beneﬁts of adding bevacizumab to a cisplatin-based
adjuvant treatment regimen for stage IIa-IIIb patients with
NSCLC and completely resected lung tumors. METHODS: A
four health state Markov Model was used to explore the effects
of adding 1 year adjuvant treatment with bevacizumab to an
existing cisplatin-based treatment regimen. Baseline survival
and relapse risks for cisplatin-treated patients are based on
published data (IALT, International Adjuvant Lung Trial). The
model uses a time-dependent risk of relapse up until six years
after surgery as well as life-long time dependent risk of death.
The effect of bevacizumab is included as a reduction in risk of
relapse based on the expected hazard ratio (HR = 0.79, FDA
approved trial protocol). The effect of bevacizumab is assumed
to be constant for ﬁve years after surgery. Outcomes include
number of relapses, life years, QALYs, direct costs (£), and
incremental cost-effectiveness ratios. A life time horizon is used
as the mean population age at surgery is 60 years. Cost and
outcomes are discounted with 3.5% per annum. Sensitivity
analysis is performed as probabilistic and deterministic sensi-
tivity analysis. RESULTS: The mean undiscounted life expect-
ancy for cisplatin-based chemotherapy treated patients was
estimated to be 10.3 years (7.4 years discounted). The addition
of bevacizumab is estimated to be increased to 11.9 years (8.4
years discounted). The discounted incremental cost-effectiveness
ratio is £39,600/QALY gained. Sensitivity analysis on key vari-
ables show that assumptions on size of risk reduction, duration
of risk reduction as well as baseline risk are the most critical
factors for the ICER. CONCLUSIONS: Adding bevacizumab to
current cisplatin-based treatment regimens for early lung cancer
is predicted to be a cost effective treatment option.
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OBJECTIVES: To evaluate the cost-effectiveness of a combined
primary (vaccination against HPV types 16 and 18) and second-
ary (population-based cervical cancer screening programme)
approach to managing Cervical Intraepithelial Neoplasia (CIN)
1–3 and cervical cancer compared to a cervical cancer screening
programme alone in the Irish health care setting. METHODS:
The economic analysis was conducted using an independently
developed dynamic agent based model [1], which takes account
of the herd immunity effect of the vaccine. The study comparator
was a population based cervical cancer screening programme.
Irish epidemiological and cost data were incorporated into the
model. The analysis was performed from the Irish health
system perspective with a time horizon of 70 years. The cost-
effectiveness of a range of catch-up vaccination strategies were
also evaluated. Costs and beneﬁts were discounted at 3.5%
per annum. A one way and probabilistic sensitivity analysis
were conducted. RESULTS: The base case incremental cost-
effectiveness ratio (ICER) was €17,383/LYG. The ICER for the
12–15 year old catch-up programme was €52,968/LYG. The key
determinants of cost effectiveness were vaccine efﬁcacy, vaccine
costs (including administration costs), duration of protection (i.e.
requirement for booster) and the discount rate. Using a proba-
bilistic sensitivity analysis about the base case, the 95% CI for
cost per LYG was (€9,658, €24,097). CONCLUSIONS: The
results of this HTA suggest that vaccination against HPV types
16 and 18 would be cost-effective from the perspective of the
Irish health care payer. Universal vaccination of 12 year old
females, against HPV types 16 and 18, can be recommended as a
cost-effective intervention in the Irish health care setting. In rela-
tion to a catch-up programme, vaccination of 12 to 15 year old
females in the ﬁrst year of the programme would be the most
cost-effective catch-up strategy. [1] Danish Centre for Health
Technology Assessment (DACEHTA). Reduction in the risk of
cervical cancer by vaccination against HPV—a health technology
assessment. Health Technology Assessment 2007;9.
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OBJECTIVES: Particle therapy (PT) with protons or carbon-ions
is a promising treatment modality for non-small cell lung cancer
(NSCLC). However, its initial investment is high, and it is unclear
whether the potential extra effects are worth the extra costs. The
cost-effectiveness of PT as opposed to stereotactic body radio-
therapy (SBRT) for inoperable stage I NSCLC was examined to
inform the adoption decision for PT. METHODS: A Markov
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model was constructed with four health states regarding survival
and irreversible adverse events. Health care costs and effects of
SBRT, proton therapy and carbon-ion therapy were compared
over a ﬁve-year time horizon. Transition probabilities were
derived from single-armed observational studies, as no compara-
tive studies were available. Utilities were collected in a cross-
sectional survey. Probabilistic sensitivity analysis was performed
to reﬂect parameter uncertainty. RESULTS: Preliminary results
showed that the expected total health care costs per patient for
SBRT were €18,366, for protons €24,267 and for carbon-ions
€26,720. The expected quality adjusted life-years (QALYs) were
2.24, 2.40 and 2.45 respectively. This resulted in an incremental
cost-effectiveness ratio (ICER) of €36,651 per QALY for protons
as opposed to SBRT, and an ICER of €44,668 per QALY for
carbon-ions as opposed to protons. For a ceiling ratio of €40,000
protons had the highest probability of being cost-effective (41%),
followed by carbon-ions (35%) and SBRT (24%). For a ceiling
ratio of €80,000 these probabilities were 42%, 52% and 6%
respectively. CONCLUSIONS: These preliminary results indicate
that PT is a potentially cost-effective treatment modality for
inoperable stage I NSCLC. However, caution is warranted, as the
differences are small and surrounded by considerable uncer-
tainty. More analyses will be performed of which the results are
presented at the conference. First, more advanced statistical tech-
niques are applied to synthesize the available evidence. Second,
for operable patients PT is compared to surgery. Third, the
cost-effectiveness of PT is assessed for stage III NSCLC. Finally,
expected value of perfect information analyses are presented to
support research decisions.
CN8
AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN
CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
IN CENTRAL AND EASTERN EUROPE
Nagy B1, Kutikova L2, Stastny M2,Vasile K3, Zsolnai Nagy I4, Mayer J5
1Healthware Consulting Ltd, Budapest, Hungary, 2Bristol-Myers Squibb,
Prague, Czech Republic, 3Bristol-Myers Squibb, Bucharest, Romania,
4Bristol-Myers Squibb, Budapest, Hungary, 5University Hospital Brno,
Brno, Czech Republic
Achieving complete cytogenetic response (CCyR) is associated
with superior progression-free survival in patients with CML [1].
How this endpoint affects cost has not been evaluated. OBJEC-
TIVES: To assess the cost needed to achieve one CCyR with
dasatinib 140 mg vs. imatinib 600 and 800 mg in imatinib-
resistant CP-CML, from the perspective of national health
insurance in the Czech Republic, Hungary and Romania.
METHODS: An economic analysis was conducted using the
number of patients needed to be treated (NNT) to achieve one
CCyR. The incremental cost for achieving CCyR in 15 months
was determined. CCyR rates for dasatinib 140 and imatinib
800 mg were based on a randomized phase 2 trial START-R [2].
Given no published data on imatinib 600 mg, its CCyR rate was
assumed to be the same as for imatinib 800 mg; an assumption in
favor of imatinib. Costs were based on reimbursed drug-prices
from national lists. In Hungary, reimbursed amounts for 600 or
800 mg of imatinib are the same. RESULTS: To achieve one
CCyR, NNT is 6,25 for imatinib and 2,5 for dasatinib. The costs
to achieve one CCyR during 15 months of therapy are CZK9,1
million (€363,172), HUF52.8 million (€218,492) and RON1.2
million (€334,146) lower for dasatinib compared to imatinib
800 mg. The economic advantage of dasatinib remains when
compared to imatinib 600 mg. The incremental costs to achieve
one CCyR between imatininb 600 mg and dasatinib are CZK5.7
million (€228,664), HUF52,8 million (€218,492) and RON0.7
million (€205,316). CONCLUSIONS: In imatinib-resistant
CP-CML patients, therapy with dasatinib provides better efﬁcacy
and lower cost compared to imatinib 600 and 800 mg in Central
and Eastern Europe to achieve one CCyR. The magnitude of the
advantage varies due to different pricing and ﬁnancing systems.
[1] Hughes et al. NEJM 2003;349:1423–32; [2] Kantarjian et al.
Blood 2007;109:5143–50.
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OBJECTIVES: Diabetes affects over 2.3 million people in UK;
approximately 10% have type 1 diabetes (T1DM). The aim of
this study was to evaluate the long-term cost and clinical out-
comes associated with lispro versus regular human insulin (RHI)
in the UK T1DM patients using the previously published and
validated CORE Diabetes Model. METHODS: Several clinical
trials have provided evidence that short-acting insulin analogs,
with improved pharmacokinetic properties, may have beneﬁts in
terms of glycaemic control (HbA1c) and hypoglycemic event
rates compared to mealtime human insulin. For the simulations,
clinical beneﬁts were derived from a recent Cochrane meta-
analysis which found the weighted mean difference in HbA1c to
be -0.1% (95% CI -0.2% to -0.0%) for treatment with lispro
versus RHI. Major hypoglycaemic event rates for lispro and RHI
were 21.8 and 46.1 per 100 patient-years, respectively. Current
prices of insulin lispro (Humalog), regular human insulin
(Humulin R) and basal NPH insulin (Humulin I) were obtained
from http://www.mims.co.uk. Complication costs and patient
management costs (screening and concomitant medications)
were derived from published sources. All costs were accounted in
2007 Pounds Sterling (£) from a National Health Service (NHS)
perspective. Future costs and clinical beneﬁts were discounted at
3.5% annually. RESULTS: Model projections indicated that
lispro was associated with a beneﬁt in quality-adjusted life
expectancy of approximately 0.10 QALYS versus RHI (7.60
versus 7.50 QALYs). Lifetime direct medical costs per patient
were lower with lispro treatment, £70,576 versus £72,529.
Lispro was projected to be dominant (lower cost: more beneﬁt)
compared to RHI. Results were robust to sensitivity analyses
including time horizon, discounting rates and scenarios assum-
ing beneﬁt only on glycaemic control or hypoglycemia rates.
CONCLUSIONS: The study suggests that lispro is likely to
improve quality-adjusted life expectancy and reduce costs in UK
patients with T1DM, due principally to beneﬁts in hypoglycemic
event rates.
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OBJECTIVES: To estimate the impact of overweight or obesity
on treatment costs(TCs) in diabetic patients in the United States.
METHODS: Five-year (2001–2005) pooled Medical Expendi-
ture Panel Survey data, a nationally representative sample of U.S.
A358 Abstracts
